



Mirum Pharmaceuticals to Provide Regulatory Update in Upcoming Conference Call and Webcast

December 13, 2019

FOSTER CITY, Calif.--(BUSINESS WIRE)--Dec. 13, 2019-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced it will provide a regulatory update in a webcast and conference call at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time on Monday, December 16, 2019.

Analysts and investors can participate in the conference call by dialing (844) 877-4019 for domestic callers and (602) 563-8495 for international callers using the conference ID# 9628308. The webcast can be accessed live on the [Investor Relations](#) page of Mirum's website, and will be available for replay for 30 days following the call.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS). For more information, visit [MirumPharma.com](#). Follow Mirum on [Twitter](#), [Facebook](#) and [LinkedIn](#).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20191213005488/en/>

Source: Mirum Pharmaceuticals, Inc.

Media Contact:

Heidi Chokeir, Ph.D.
Canale Communications
619-203-5391
heidi@canalecomm.com

Investor Contact:

Ian Clements, Ph.D.
650-667-4085
ir@mirumpharma.com